Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.
Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
Higher levels of consumption of green tea and/or coffee may reduce mortality in those with T2DM.
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes.
Dose-response association shows higher risk for dementia with HbA1c >87 versus <52 mmol/mol.
Increased risk for cardiovascular disease observed in offspring for up to 35 years of follow-up.
Responders had increase in pancreas volume, normalization of irregular pancreas borders.